Cargando…
Clinical trials in the pandemic age: What is fit for purpose?
It is critical to ensure that COVID-19 studies provide clear and timely answers to the scientific questions that will guide us to scalable solutions for all global regions. Significant challenges in operationalizing trials include public policies for managing the pandemic, public health and clinical...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000 Research Limited
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324688/ https://www.ncbi.nlm.nih.gov/pubmed/32656501 http://dx.doi.org/10.12688/gatesopenres.13146.1 |
_version_ | 1783551991615586304 |
---|---|
author | Hartman, Dan Heaton, Penny Cammack, Nick Hudson, Ian Dolley, Shawn Netsi, Elena Norman, Thea Mundel, Trevor |
author_facet | Hartman, Dan Heaton, Penny Cammack, Nick Hudson, Ian Dolley, Shawn Netsi, Elena Norman, Thea Mundel, Trevor |
author_sort | Hartman, Dan |
collection | PubMed |
description | It is critical to ensure that COVID-19 studies provide clear and timely answers to the scientific questions that will guide us to scalable solutions for all global regions. Significant challenges in operationalizing trials include public policies for managing the pandemic, public health and clinical capacity, travel and migration, and availability of tests and infrastructure. These factors lead to spikes and troughs in patient count by location, disrupting the ability to predict when or if a trial will reach recruitment goals. The focus must also be on understanding how to provide equitable access to these interventions ensuring that interventions reach those who need them the most, be it patients in low resource settings or vulnerable groups. We introduce a website to be used by The Bill & Melinda Gates Foundation, Wellcome Trust, and other funders of the COVID Therapeutics Accelerator that accept proposals for future clinical research. The portal enables evaluations of clinical study applications that focus on study qualities most likely to lead to informative outcomes and completed studies. |
format | Online Article Text |
id | pubmed-7324688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | F1000 Research Limited |
record_format | MEDLINE/PubMed |
spelling | pubmed-73246882020-07-09 Clinical trials in the pandemic age: What is fit for purpose? Hartman, Dan Heaton, Penny Cammack, Nick Hudson, Ian Dolley, Shawn Netsi, Elena Norman, Thea Mundel, Trevor Gates Open Res Open Letter It is critical to ensure that COVID-19 studies provide clear and timely answers to the scientific questions that will guide us to scalable solutions for all global regions. Significant challenges in operationalizing trials include public policies for managing the pandemic, public health and clinical capacity, travel and migration, and availability of tests and infrastructure. These factors lead to spikes and troughs in patient count by location, disrupting the ability to predict when or if a trial will reach recruitment goals. The focus must also be on understanding how to provide equitable access to these interventions ensuring that interventions reach those who need them the most, be it patients in low resource settings or vulnerable groups. We introduce a website to be used by The Bill & Melinda Gates Foundation, Wellcome Trust, and other funders of the COVID Therapeutics Accelerator that accept proposals for future clinical research. The portal enables evaluations of clinical study applications that focus on study qualities most likely to lead to informative outcomes and completed studies. F1000 Research Limited 2020-06-09 /pmc/articles/PMC7324688/ /pubmed/32656501 http://dx.doi.org/10.12688/gatesopenres.13146.1 Text en Copyright: © 2020 Hartman D et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Open Letter Hartman, Dan Heaton, Penny Cammack, Nick Hudson, Ian Dolley, Shawn Netsi, Elena Norman, Thea Mundel, Trevor Clinical trials in the pandemic age: What is fit for purpose? |
title | Clinical trials in the pandemic age: What is fit for purpose? |
title_full | Clinical trials in the pandemic age: What is fit for purpose? |
title_fullStr | Clinical trials in the pandemic age: What is fit for purpose? |
title_full_unstemmed | Clinical trials in the pandemic age: What is fit for purpose? |
title_short | Clinical trials in the pandemic age: What is fit for purpose? |
title_sort | clinical trials in the pandemic age: what is fit for purpose? |
topic | Open Letter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324688/ https://www.ncbi.nlm.nih.gov/pubmed/32656501 http://dx.doi.org/10.12688/gatesopenres.13146.1 |
work_keys_str_mv | AT hartmandan clinicaltrialsinthepandemicagewhatisfitforpurpose AT heatonpenny clinicaltrialsinthepandemicagewhatisfitforpurpose AT cammacknick clinicaltrialsinthepandemicagewhatisfitforpurpose AT hudsonian clinicaltrialsinthepandemicagewhatisfitforpurpose AT dolleyshawn clinicaltrialsinthepandemicagewhatisfitforpurpose AT netsielena clinicaltrialsinthepandemicagewhatisfitforpurpose AT normanthea clinicaltrialsinthepandemicagewhatisfitforpurpose AT mundeltrevor clinicaltrialsinthepandemicagewhatisfitforpurpose |